Toleranzia AB Sustainability Reports
Toleranzia AB develops drugs that harness the power of the immune system to treat autoimmune orphan diseases. Its primary focus is on therapies targeting the underlying cause of myasthenia gravis using its lead drug candidate TOL2.
Sector: Manufacturing
Country: Sweden
Exchange: Nasdaq Stockholm
LEI: 529900ARVN1D3A4CHI81
FIGI: BBG007K8S3T6
1 reports from 2024 to 2024